ERBB2 and neoplasm: Our preclinical study agreed with two other studies in which CAR-expressing T cells exhibited robust antitumor activity in targeting HER2 positive xenogeneic mouse tumor models (Liu X et al., 2015; Nakazawa Y et al., 2011).